GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Pretax Margin %

Insmed (Insmed) Pretax Margin % : -221.12% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Insmed's Pre-Tax Income for the three months ended in Dec. 2023 was $-185.1 Mil. Insmed's Revenue for the three months ended in Dec. 2023 was $83.7 Mil. Therefore, Insmed's pretax margin for the quarter that ended in Dec. 2023 was -221.12%.

The historical rank and industry rank for Insmed's Pretax Margin % or its related term are showing as below:

INSM' s Pretax Margin % Range Over the Past 10 Years
Min: -3295.13   Med: -213.63   Max: -178.02
Current: -244.76


INSM's Pretax Margin % is ranked worse than
54.92% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs INSM: -244.76

Insmed Pretax Margin % Historical Data

The historical data trend for Insmed's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Pretax Margin % Chart

Insmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -185.80 -178.02 -231.57 -195.69 -244.76

Insmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -269.81 -244.24 -316.30 -200.31 -221.12

Competitive Comparison of Insmed's Pretax Margin %

For the Biotechnology subindustry, Insmed's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Insmed's Pretax Margin % falls into.



Insmed Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Insmed's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-747.012/305.208
=-244.76 %

Insmed's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-185.063/83.693
=-221.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insmed  (NAS:INSM) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Insmed Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Insmed's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed (Insmed) Business Description

Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Executives
Flammer Martina M.d. officer: Chief Medical Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett officer: Chief Commercial Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise officer: Chief Commercial Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith officer: General Counsel, Senior VP 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis officer: President & CEO 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole officer: Chief People Strategy Officer INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano officer: Chief Compliance Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari officer: General Counsel & Secretary 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807